{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-054869","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2021-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.821479+00:00","generated_at":"2026-06-28T17:26:18.378874+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"medium","headline":"Silo Pharma partners with Columbia University on ketamine-based Alzheimer's therapeutic","bullets":["Sponsored research agreement with Columbia University to develop ketamine treatment for Alzheimer's disease.","Option to license novel inventions from Dr. Christine Ann Denny's lab targeting memory and cognitive aging.","No financial terms or specific milestones disclosed in the agreement.","Silo Pharma (OTCQB: SILO) is a development-stage biopharmaceutical company focused on psychedelics."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-054869","json":"https://secwatch.observer/filing/0001213900-21-054869.json","markdown":"https://secwatch.observer/filing/0001213900-21-054869.md","text":"https://secwatch.observer/filing/0001213900-21-054869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390021054869/0001213900-21-054869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390021054869/ea149452-8k_silopharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T17:26:18.378874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}